News tagged with myeloid leukemia
ATRA and arsenic trioxide versus ATRA and idarubicin for newly diagnosed, non high-risk acute promyelocytic
New research demonstrates the efficacy of the first curative treatment for acute promyelocytic leukemia (APL) that does not include chemotherapy, marking an important step toward front-line use of targeted therapies for acute ...
Cancer
Dec 09, 2012 |
not rated yet |
0
Clinical trial delivers good results in leukemia patients
Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard ...
Cancer
Nov 30, 2012 |
not rated yet |
0
Ponatinib acts against the most resistant types of chronic myeloid leukemia
A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.
Cancer
Nov 28, 2012 |
not rated yet |
0
|
A code of silence in acute myeloid leukemia
The development of acute myeloid leukemia (AML) is associated with a variety of genetic changes. Some of these alterations are epigenetic, wherein the sequence of the genes is unchanged, but chemical modifications to the ...
Cancer
Nov 19, 2012 |
5 / 5 (1) |
0
Gene sequencing project identifies abnormal gene that launches rare childhood leukemia
Research led by the St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with ...
Cancer
Nov 12, 2012 |
not rated yet |
0
|
Researchers report first effective treatment of tumors arising from common genetic disease NF1
Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.
Cancer
Nov 01, 2012 |
3 / 5 (1) |
0
|
Better prognosis for early blast clearance in leukemia
(HealthDay)—Patients with acute myeloid leukemia whose peripheral blood blasts clear in six days or less after chemotherapy have significantly better survival than patients whose peripheral blasts clear ...
Cancer
Oct 24, 2012 |
5 / 5 (1) |
0
Researcher investigate 2-drug synergy to treat drug-resistant chronic myeloid leukemia
(Medical Xpress)—An interdisciplinary team of researchers has dissected a case of synergy in drug-resistant chronic myeloid leukemia to understand the mechanism by which two drugs, danusertib and bosutinib, work together ...
Cancer
Oct 24, 2012 |
not rated yet |
0
|
Researcher pieces together AML prognosis puzzle
When patients suffering from Acute Myeloid Leukemia (AML) express high levels of the gene, MN1, an already aggressive leukemia is accelerated and shortens survival time. While that's a known fact, the mechanisms involved ...
Cancer
Oct 15, 2012 |
not rated yet |
0
|
New tool determines leukemia cells' 'readiness to die,' may guide clinical care
Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more ...
Cancer
Oct 11, 2012 |
5 / 5 (1) |
0
|
RNA interference for human therapy
Leading scientists in the field investigated the potential of RNA interference (RNAi) technology as a therapeutic intervention for down-regulating the expression of disease-associated genes. Project deliverables ...
Medical research
Sep 20, 2012 |
not rated yet |
0
Researchers find novel predictor for MDS progression risk
Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) ...
Immunology
Sep 13, 2012 |
not rated yet |
0
|
Improved diagnostic test benefits children with acute myeloid leukemia
Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research ...
Cancer
Sep 10, 2012 |
not rated yet |
0
New genetic mechanism for controlling blood cell development and blood vessel integrity found
The protein GATA2 is known as a "master regulator" of blood cell development. When a mutation occurs in the gene that makes GATA2, serious blood diseases such as acute myeloid leukemia can result.
Genetics
Sep 10, 2012 |
not rated yet |
0
|
FDA approves Pfizer drug for rare blood cancer
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.
Medications
Sep 04, 2012 |
not rated yet |
0
